NZ740157A - Methods of improving myocardial performance in fontan patients using udenafil compositions - Google Patents

Methods of improving myocardial performance in fontan patients using udenafil compositions

Info

Publication number
NZ740157A
NZ740157A NZ740157A NZ74015715A NZ740157A NZ 740157 A NZ740157 A NZ 740157A NZ 740157 A NZ740157 A NZ 740157A NZ 74015715 A NZ74015715 A NZ 74015715A NZ 740157 A NZ740157 A NZ 740157A
Authority
NZ
New Zealand
Prior art keywords
udenafil
methods
fontan
patients
myocardial performance
Prior art date
Application number
NZ740157A
Other versions
NZ740157B2 (en
Inventor
James L Yeager
David J Goldberg
Stephen M Paridon
Original Assignee
The Children’S Hospital Of Philadelphia
Mezzion Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Children’S Hospital Of Philadelphia, Mezzion Pharma Co Ltd filed Critical The Children’S Hospital Of Philadelphia
Priority to NZ765796A priority Critical patent/NZ765796B2/en
Priority to NZ765800A priority patent/NZ765800A/en
Publication of NZ740157A publication Critical patent/NZ740157A/en
Publication of NZ740157B2 publication Critical patent/NZ740157B2/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates generally to the field of using udenafil or a pharmaceutically acceptable salt thereof in patients who have undergone the Fontan operation. Udenafil is administered to patients whose exercise capacity is adversely affected due to a decline in heart function after Fontan palliation, with a total daily dose of 125 mg to 175 mg. Improvement of exercise capacity is determined by maximum oxygen uptake at maximum exercise output (VO2 measurement).
NZ740157A 2014-08-12 2015-06-30 Methods of improving myocardial performance in fontan patients using udenafil compositions NZ740157B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
NZ765796A NZ765796B2 (en) 2015-06-30 Methods of improving myocardial performance in fontan patients using udenafil compositions
NZ765800A NZ765800A (en) 2014-08-12 2015-06-30 Methods of improving myocardial performance in fontan patients using udenafil compositions

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462036506P 2014-08-12 2014-08-12
US201562186132P 2015-06-29 2015-06-29
NZ72765315 2015-06-30

Publications (2)

Publication Number Publication Date
NZ740157A true NZ740157A (en) 2023-09-29
NZ740157B2 NZ740157B2 (en) 2024-01-04

Family

ID=

Similar Documents

Publication Publication Date Title
PH12017501321A1 (en) Oral care compositions and methods of use
NZ735575A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
MX2016010213A (en) Novel pharmaceutical formulations.
EA201692280A1 (en) CONNECTIONS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY
NZ732391A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
MY200278A (en) Methods of improving exercise capacity in fontan patients using udenafil compositions
PH12014502217A1 (en) Methods for improving diaphragm function
PH12015501375B1 (en) Stable metal ion containing compositions
MX366368B (en) Prebiotic oral care methods using a saccharide.
MX2017016801A (en) Drospirenone-based contraceptive for a female patient affected with excess weight.
MX2018005415A (en) Durable dental film-forming composition and uses thereof.
BR112015007592A2 (en) enalapril compositions
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
ZA202208504B (en) Intradialytic use of sodium nitrite
MX2021006488A (en) Compositions for improving sexual function.
EA201890929A1 (en) LOW DOSES OF DIPYRIDAMOL COMPOSITIONS FOR ORAL ADMINISTRATION AND THEIR USE
NZ740157A (en) Methods of improving myocardial performance in fontan patients using udenafil compositions
MX2018002034A (en) Prophylaxis of hypertension and cardiovascular diseases.
MX2017007847A (en) Oral care composition.
PH12019502685A1 (en) Use of citrulline and glutathione to increase muscle mass
PH12018502339B1 (en) Oral care composition
GEP20156373B (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease
MX2017007422A (en) Oral care composition.
EA201892664A1 (en) COMPOSITION FOR CARE OF THE ORAL CAVITY
UA91081U (en) Method for simulation of cataract

Legal Events

Date Code Title Description
PSEA Patent sealed